Bryan Garnier Downgrades MorphoSys to Neutral

Bryan Garnier analyst Victor Floc'h downgrades MorphoSys (NASDAQ:MOR) from Buy to Neutral.

byBenzinga Newsdesk

June 3, 2021

1 minute read

Bryan Garnier analyst Victor Floc’h downgrades MorphoSys (NASDAQ:MOR) from Buy to Neutral.

Oncternal Therapeutics Announces Clinical Trial Collaboration To Advance Zilovertamab Phase 3 Study In Combination With Ibrutinib For Patients With MCL

By Benzinga Newsdesk

Today, 10:41 AM

Clinical trial collaboration supports global registrational Phase 3 study ZILO-301, to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinib Agreement is supportive of the planned initiation

ONCT

Deutsche Bank Maintains Hold on H.B. Fuller, Lowers Price Target to $72

By Benzinga Newsdesk

Today, 10:41 AM

Deutsche Bank analyst David Begleiter maintains H.B. Fuller (NYSE:FUL) with a Hold and lowers the price target from $80 to $72.

FUL

4D Molecular Therapeutics Early Sunday Highlighted Presentation Of Interim Results From Ongoing 4D-125 Phase 1/2 Trial In Patients With Advanced X-Linked Retinitis Pigmentosa At American Society Of Retina Specialists Meeting

By Benzinga Newsdesk

Today, 10:41 AM

4D-125 was well tolerated in all patients treated to-date (n=8), with no dose-limiting toxicities, no serious adverse events and no chronic inflammation Clinical activity observed through anatomical

FDMT

Why Aurora Cannabis Stock Is Trading Higher Today

By Adam Eckert

Today, 10:41 AM

Aurora Cannabis Inc (NASDAQ: ACB) is trading higher Friday in sympathy with Sundial Growers Inc (NASDAQ: SNDL), which reported its third-quarter financial results and announced a share repurchase program.<

ACB

Bryan Garnier Downgrades MorphoSys to Neutral

Related Posts

Oncternal Therapeutics Announces Clinical Trial Collaboration To Advance Zilovertamab Phase 3 Study In Combination With Ibrutinib For Patients With MCL

Deutsche Bank Maintains Hold on H.B. Fuller, Lowers Price Target to $72

4D Molecular Therapeutics Early Sunday Highlighted Presentation Of Interim Results From Ongoing 4D-125 Phase 1/2 Trial In Patients With Advanced X-Linked Retinitis Pigmentosa At American Society Of Retina Specialists Meeting

Why Aurora Cannabis Stock Is Trading Higher Today